KeyBanc Keeps Their Buy Rating on Cooper Co (COO)

KeyBanc analyst Matthew Mishan maintained a Buy rating on Cooper Co (COOResearch Report) today and set a price target of $351.00. The company’s shares closed last Monday at $313.18.

According to, Mishan is a 4-star analyst with an average return of 14.1% and a 72.7% success rate. Mishan covers the Healthcare sector, focusing on stocks such as Becton Dickinson, Avanos Medical, and Angiodynamics.

Currently, the analyst consensus on Cooper Co is a Strong Buy with an average price target of $356.33, representing a 14.1% upside. In a report issued on November 17, Piper Jaffray also reiterated a Buy rating on the stock with a $360.00 price target.

See today’s analyst top recommended stocks >>

Based on Cooper Co’s latest earnings release for the quarter ending July 31, the company reported a quarterly net profit of $120 million. In comparison, last year the company had a net profit of $101 million.

Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of COO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Cooper Cos, Inc. operates as a medical device company. It operates through the following business units: Cooper Vision and Cooper Surgical. The Cooper Vision business unit brings a refreshing perspective on vision care with a commitment to crafting quality lenses for contact lens wearers.